Quantcast
Channel: Endpoints News

FDA approves new dosing of Lilly’s Alzheimer’s drug Kisunla to lower brain...

Eli Lilly’s new Alzheimer’s drug is off to a slow start, but the Indianapolis drugmaker hopes that an update to the treatment’s prescription label may help build confidence among doctors and patients ...

View Article


Merck to buy respiratory drugmaker Verona Pharma for $10B

Merck is boosting its respiratory portfolio with a $10 billion takeover of commercial-stage drugmaker Verona Pharma, the companies said Wednesday morning. It signals Merck’s ongoing appetite for large...

View Article


AstraZeneca’s Alexion inks AAV capsid deal with JCR Pharma

AstraZeneca’s rare disease business Alexion returns to JCR Pharmaceuticals for another deal, this time for a pact worth up to $825 million for its adeno-associated virus capsids. Alexion will use JCR’s...

View Article

Revolution and Iambic sign AI R&D deal for cancer drugs

Revolution Medicines has become one of the industry's most valuable pre-commercial companies thanks to its pipeline of clinical-stage cancer drugs. CEO Mark Goldsmith is pressing ahead on what could be...

View Article

Rhythm says oral rare obesity drug clears Phase 2 test, plans tweaks to...

Rhythm Pharmaceuticals said Wednesday its oral candidate for a rare form of obesity produced “statistically significant and clinically meaningful” reductions in BMI in a mid-stage trial. The biotech...

View Article


Trump’s CDC nominee Monarez advances to full Senate

Susan Monarez's nomination for CDC director cleared the Senate health committee on Wednesday, putting her one step closer to leading the agency after an upheaval of its vaccine advisers. If confirmed...

View Article

Biopharma pay analysis: Highest-paying drugmakers of 2024

The typical employee at a publicly traded life sciences company made $224,729 last year, according to an Endpoints News analysis of pay trends across the industry. Endpoints reviewed hundreds of annual...

View Article

Novartis' brain delivery platform option deal worth up to $175M; Neumora's...

View Article


CoRegen closes $93M financing round to enter the clinic

Clinical-stage gene therapy biotech CoRegen has secured $93.4 million in a financing round to develop its manufacturing processes, fund its first clinical study and build up its leadership team. The...

View Article


Retiring Arvinas CEO reflects on his time leading the PROTAC company

Arvinas CEO John Houston is planning to retire after more than eight years at the helm, the company announced Wednesday, as its lead protein degrader program approaches an inflection point. Arvinas has...

View Article

J&J prevails in schizophrenia drug patent spat against Teva

Johnson & Johnson beat back Teva's patent challenge in a federal appeals court ruling that closes out a yearslong fight over J&J’s antipsychotic medication Invega Sustenna. The US Court of...

View Article

Federal judge sides with FDA on its mifepristone rules

The FDA acted within its purview when it maintained some safety requirements for the abortion pill mifepristone following an agency review, a federal court in Washington ruled. “The Court cannot find,...

View Article

FDA’s pediatric adcomm votes to continue surveillance of 21 drugs, three...

The FDA’s pediatric advisory committee voted almost unanimously to continue monitoring 21 drugs and three vaccines for side effects, including blockbusters such as Novartis’ heart drug Entresto and...

View Article


Aqtual raises $31M to guide rheumatoid arthritis treatments

View Article

Swiss and German radiopharma biotech Nuclidium collects $99M Series B

For the second day in a row, a European radiopharma company said it has bagged a large venture funding round. Basel and Munich-based startup Nuclidium has pulled together a CHF 79 million (about $99...

View Article


Kidney health biotech Renasant Bio emerges with $54M to follow in Vertex’s...

A Berkeley, CA-based biotech that wants to replicate Vertex’s success with corrector and potentiator medicines has raised a $54.5 million seed round. The funding, disclosed Thursday morning, will help...

View Article

Ultragenyx, Mereo’s bone disease drug fails second interim analysis, stocks...

Ultragenyx Pharmaceutical and Mereo BioPharma’s antibody for a rare bone disease failed a second interim analysis in its pivotal trial, the companies revealed late on Wednesday. The study will continue...

View Article


Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

The numbers aren’t all bad in biotech. But you’d be forgiven if you thought they were. And you’d be in good company. Once again, Chris Dokomajilar at DealForma has been checking the data for us ...

View Article

Endpoints livestream: Curie.Bio CEO Zach Weinberg on China biotech competition

Today on Post-Hoc Live, we're talking about China — and how some in biotech want to make it harder for US companies to do deals there. The drug industry has turned to China for new molecules ...

View Article

A state bill threatens to ban AI therapists, forcing health tech startups to...

AI therapists could soon be banned for the first time in the US under an Illinois bill, as mental health companies scramble to comply. The Wellness and Oversight for Psychological Resources Act forbids...

View Article

DHL’s $700M+ expansion in UK and Ireland; Novo Nordisk’s quality testing site...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. DHL Supply Chain has invested £550 million ($748 million) to expand...

View Article


Soleno's first wave of rare disease drug sales beats expectations

The first full quarter sales for Soleno Therapeutics’ rare disease drug Vykat XR are in, and they have exceeded investor forecasts. Soleno said Thursday morning that Vykat XR ...

View Article


For first time ever, FDA publishes drug rejection letters

In a historic first, the FDA on Thursday released about 200 novel and generic drug rejection letters, bucking the agency's former unwillingness to release the documents. But it's a small step ...

View Article

AstraZeneca hands over opioid addiction pill to Eolas; TandemAI, Perpetual...

Plus, news about Pfizer and Astellas' Xtandi, BeOne Medicines, Biocytogen and Rhythm: Eolas Therapeutics takes opioid addiction pill from AstraZeneca: The biotech will assume full development rights ...

View Article